Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.12% | -34.06% | -39.99% | -32.45% | -10.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.12% | -34.06% | -39.99% | -32.45% | -10.26% |
| Cost of Revenue | -18.80% | -27.02% | -34.22% | -44.25% | -18.87% |
| Gross Profit | -14.64% | -37.61% | -42.99% | -25.21% | -4.62% |
| SG&A Expenses | 9.11% | -12.29% | -50.58% | -49.98% | -52.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.14% | -14.26% | -49.04% | -49.41% | -49.54% |
| Operating Income | -19.07% | 0.96% | 52.51% | 55.36% | 60.77% |
| Income Before Tax | -84.38% | 7.74% | -162.34% | -144.79% | -147.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.38% | 7.74% | -162.34% | -144.79% | -147.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.38% | 7.74% | -162.34% | -144.79% | -147.76% |
| EBIT | -19.07% | 0.96% | 52.51% | 55.36% | 60.77% |
| EBITDA | -20.31% | -0.24% | 52.34% | 55.43% | 61.06% |
| EPS Basic | -100.00% | 0.00% | -133.33% | -125.00% | -133.33% |
| Normalized Basic EPS | -- | -- | -100.00% | -100.00% | -100.00% |
| EPS Diluted | -100.00% | 0.00% | -- | -- | 0.00% |
| Normalized Diluted EPS | -- | -- | -100.00% | -100.00% | -100.00% |
| Average Basic Shares Outstanding | 0.83% | 0.87% | 0.57% | 0.50% | 0.73% |
| Average Diluted Shares Outstanding | 0.83% | 0.87% | -43.24% | -50.64% | -50.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |